|Bid||21.20 x 25800|
|Ask||21.80 x 24800|
|Day's Range||20.40 - 21.60|
|52 Week Range||16.60 - 27.00|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 06, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
LATHAM, N.Y., September 08, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market open on Thursday, October 6, 2022. The Company’s management will host a conference call at 8:00 a.m. ET the s
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.